Your AI-Trained Oncology Knowledge Connection!

Improving Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

home / peer-exchange / improving-outcomes-in-relapsed-refractory-diffuse-large-b-cell-lymphoma

Standard of Care for Treatment of DLBCL

EP. 1: Standard of Care for Treatment of DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Prognosis of R/R DLBCL

EP. 2: Prognosis of R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Treatment in Transplant-ineligible R/R DLBCL

EP. 3: Treatment in Transplant-ineligible R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Role of CAR T-cell Therapy in R/R DLBCL

EP. 4: Role of CAR T-cell Therapy in R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

ASCO 2020 Data: CAR T in R/R DLBCL

EP. 5: ASCO 2020 Data: CAR T in R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

CAR T in R/R DLBCL: Safety and Patient Selection

EP. 6: CAR T in R/R DLBCL: Safety and Patient Selection

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

CD19-Directed Therapies for Treatment of R/R DLBCL

EP. 7: CD19-Directed Therapies for Treatment of R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

EP. 8: Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Safety and Efficacy of Oral Agents in R/R DLBCL

EP. 9: Safety and Efficacy of Oral Agents in R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Emerging Therapies for R/R DLBCL

EP. 10: Emerging Therapies for R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Improving Outcomes in Patients With R/R DLBCL

EP. 11: Improving Outcomes in Patients With R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Closing Thoughts on Treatment of R/R DLBCL

EP. 12: Closing Thoughts on Treatment of R/R DLBCL

By Nathan H. Fowler, MD, MD Anderson Cancer Center
John P. Leonard, MD, Weill Cornell Medicine

Latest Conference Coverage

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Download on Apple

© 2025 MJH Life Sciences

All rights reserved.